Turtle Cameron 4
4 · Spyre Therapeutics, Inc. · Filed Nov 27, 2023
Insider Transaction Report
Form 4
Turtle Cameron
DirectorChief Executive Officer
Transactions
- Conversion
Series A Preferred Stock
2023-11-24−18,086→ 0 total→ Common Stock (723,440 underlying) - Award
Stock Option (Right to Buy)
2023-11-22+374,000→ 374,000 totalExercise: $10.39Exp: 2033-11-22→ Common Stock (374,000 underlying) - Conversion
Common Stock
2023-11-24+723,440→ 746,507 total
Footnotes (4)
- [F1]Following stockholder approval of the conversion of Series A preferred stock into shares of common stock, each share of Series A preferred stock automatically converted on November 24, 2023 into 40 shares of common stock, subject to certain limitations.
- [F2]Includes 506,440 shares of common stock that vest over an approximately three year period, subject to the continuing service of the Reporting Person on each vesting date.
- [F3]Includes 522,588 shares of common stock that vest over an approximately three year period, subject to the continuing service of the Reporting Person on each vesting date.
- [F4]This option represents a right to purchase 374,000 shares of the Issuer's common stock, one quarter of which will vest and become exercisable on November 22, 2024, with the remaining three quarters vesting in equal monthly installments over the following three years, subject to the Reporting Person's continued employment with the Issuer at each vesting date.